{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031249","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.529591+00:00","generated_at":"2026-06-08T06:08:32.203228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omeros Q3 net loss $37.8M; discontinues IgA nephropathy trial, targets narsoplimab BLA in mid-2024","bullets":["Net loss of $37.8M ($0.60/sh) vs $17.5M prior year; continuing ops loss $51.7M, down from $54.8M.","OMIDRIA royalties $10.0M on $33.3M US sales (down from $16.5M) due to royalty rate drop to 30%.","$310.3M cash as of Sept 30; expects to repay $95M convertible notes due Nov 15, 2023.","Phase 3 ARTEMIS-IGAN trial for IgA nephropathy discontinued after interim analysis missed primary endpoint.","BLA resubmission for narsoplimab in TA-TMA on track for FDA decision mid-2024; OMS906 Phase 2 PNH data pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031249","json":"https://secwatch.observer/filing/0001437749-23-031249.json","markdown":"https://secwatch.observer/filing/0001437749-23-031249.md","text":"https://secwatch.observer/filing/0001437749-23-031249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/0001437749-23-031249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/omer20230905_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:08:32.203228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"079d01fcfeac04779fd55b41f643ab6bf55d5b51","claim":"OMEROS CORP reported third quarter ended September 30, 2023 results: net income Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share, EPS $0.60 per share.","evidence_excerpt":"Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share, compared to a net loss in the prior year quarter of $17.5 million, or $0.28 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/0001437749-23-031249-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share"},{"label":"EPS","value":"$0.60 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"1ec4bdcc6d86541b5ff11ab55bd0257efe3da86d","claim":"OMEROS CORP reported nine months ended September 30, 2023 results: net income net loss was $108.8 million, or $1.73 per share, EPS $1.73 per share.","evidence_excerpt":"For the nine months ended September 30, 2023, our net loss was $108.8 million, or $1.73 per share, compared to a net loss of $81.3 million, or $1.30 per share, in the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/0001437749-23-031249-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Net income","value":"net loss was $108.8 million, or $1.73 per share"},{"label":"EPS","value":"$1.73 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}